Preference for different PrEP formulations: A cross‐sectional study in a PrEP cohort in Spain
HIV Medicine · 2026
DOI: 10.1111/hiv.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Alfredo Soler-Carracedo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chelsea and Westminster Hospital, London, UK. Hauptthemen laut MEDLINE: Patient Preference, Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
To gain a better understanding of PrEP‐users' preference for long‐acting vs. oral PrEP formulation.
Methods
From April 2023 to January 2024, participants who were prescribed PrEP completed an anonymous, structured, self‐administered, cross‐sectional survey as part of their routine PrEP care in a hospital setting in Madrid, Spain. Inclusion criteria were attendance at the clinic for PrEP care and the ability to understand the Spanish language. Eligibility was not restricted by age. A convenience sample of 200 participants was used. The ethics committee approved a waiver of written consent. Descriptive statistics and chi‐square tests were used to analyse the data.
Results
A sample of 201 participants completed the survey, of which 193 (96.5%) were male and most were 30–39 years old (48.8%). The response rate was estimated to be more than 90%. Among participants, 74.9% preferred LA‐PrEP (53.9% preferred a subcutaneous (SC) injection every 6 months and 21.0% preferred an intramuscular (IM) injection every 2 months). Participants reported that LA‐PrEP is more practical, indicating fewer visits to the clinic as a primary reason (67.4%). 29.4% of participants were aware of IM LA‐PrEP, 10.0% of SC LA‐PrEP and 10.4% were familiar with both. Respondents who selected LA‐PrEP were more often under 40 years of age ( p = 0.016) compared to those who preferred oral PrEP (73.7% vs. 61.2%, respectively). Limitations included the use of a cross‐sectional design, a homogeneous sample and the use of one study location, among others.
Conclusion
LA‐PrEP is the preferred form of PrEP for the majority of respondents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chelsea and Westminster Hospital, London, UK.
- University of Washington, Seattle, Washington, USA.
- Hospital Universitario La Paz, Madrid, Spain.
- Imperial College, London, UK.
- The University of Miami, Coral Gables, Florida, USA.
ORCID-Profile: Alfredo Soler-Carracedo, Luis Ramos-Ruperto, Rafael Mican-Rivera, Stephanie A Ruderman, Joseph P De Santis, Jose I Bernardino
Zitieren
APA
Soler-Carracedo, A., Webel, A. R., Ramos-Ruperto, L., Mican-Rivera, R., Montejano-Sanchez, R., Milinkovic, A., Ruderman, S. A., De Santis, J. P., & Bernardino, J. I. (2026). Preference for different PrEP formulations: A cross‐sectional study in a PrEP cohort in Spain. HIV Medicine. https://doi.org/10.1111/hiv.70252
Vancouver
Soler-Carracedo A, Webel AR, Ramos-Ruperto L, Mican-Rivera R, Montejano-Sanchez R, Milinkovic A, et al. Preference for different PrEP formulations: A cross‐sectional study in a PrEP cohort in Spain. HIV Medicine. 2026. doi:10.1111/hiv.70252
BibTeX
@article{SolerCarracedo2026,
author = {Soler-Carracedo, Alfredo and Webel, Allison R and Ramos-Ruperto, Luis and Mican-Rivera, Rafael and Montejano-Sanchez, Rocio and Milinkovic, Ana and Ruderman, Stephanie A and De Santis, Joseph P and Bernardino, Jose I},
title = {Preference for different PrEP formulations: A cross‐sectional study in a PrEP cohort in Spain},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70252}
}
EUVIMED